TRIM22 and central nervous system cancer: In vivo studies within murine glioma models show that GSK761 inhibits glioma progression via TRIM22 downregulation and downregulation of the PI3K/AKT pathway, which suggests that SP140 inhibition may allow for reduced glioma invasiveness [74].